Graftide M 500mg Tablet

• Prevention of organ rejection in transplant patients

Like any other medicine, Graftide M 500mg Tablet also has some common to severe side effects. These undesired symptoms observed in the body after taking this injection and usually disappear with time as the body adjusts to the medicine.

Common Side Effects Include:

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Headache
• High blood pressure
• Decreased white blood cell count (neutrophils)
• Bacterial infection
• Fungal infection
• Pneumonia
• Increased uric acid level in blood
• Electrolyte imbalance
• Anxiety
• Breathlessness
• Increased creatinine level in blood
• Anemia (low number of red blood cells)
• Acne
• Muscle pain

However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

• Doctor will decide the dose and duration of Graftide M 500mg Tablet based on the type of transplant you have and other factors such as body weight and age. Swallow the whole tablet with a glass of water as it is an orally available drug.
• This tablet can be taken with or without food but on the fixed time everyday to get better results. Take it exactly as advice by the doctor, don't miss a dose or over dose the medicine.
  
  

• Graftide M 500mg Tablet contains Mycophenolate mofetil (500mg) as an active ingredient that belongs to the immunosuppressant class of drugs.
• It works by weakening the body’s immune system and reduces its action to prevent the attack on a transplanted organ or rejection of the transplanted organ.
  
  

• Sievers, T. M., Rossi, S. J., Ghobrial, R. M., Arriola, E., Nishimura, P., Kawano, M., & Holt, C. D. (1997). Mycophenolate mofetil. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 17(6), 1178-1197. https://pubmed.ncbi.nlm.nih.gov/9399601/
• Doycheva, D., Deuter, C., Stuebiger, N., Biester, S., & Zierhut, M. (2007). Mycophenolate mofetil in the treatment of uveitis in children. British journal of ophthalmology, 91(2), 180-184. https://pubmed.ncbi.nlm.nih.gov/16825275/
• Lipsky, J. J. (1996). Mycophenolate mofetil. The Lancet, 348(9038), 1357-1359. https://pubmed.ncbi.nlm.nih.gov/8918281/
• Huh, S. Y., Kim, S. H., Hyun, J. W., Joung, A. R., Park, M. S., Kim, B. J., & Kim, H. J. (2014). Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA neurology, 71(11), 1372-1378. https://pubmed.ncbi.nlm.nih.gov/25199960/
• Touma, Z., Gladman, D. D., Urowitz, M. B., Beyene, J., Uleryk, E. M., & Shah, P. S. (2011). Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. The Journal of rheumatology, 38(1), 69-78. https://pubmed.ncbi.nlm.nih.gov/20952473/
• Preddie, D. C., Markowitz, G. S., Radhakrishnan, J., Nickolas, T. L., D’Agati, V. D., Schwimmer, J. A., ... & Appel, G. B. (2006). Mycophenolate mofetil for the treatment of interstitial nephritis. Clinical Journal of the American Society of Nephrology, 1(4), 718-722. https://pubmed.ncbi.nlm.nih.gov/17699278/